Table 2.
Correlation between the FR+-CTC count and clinical characteristics.
| Characteristics | CTC expression level | χ2 | p | Characteristics | CTC expression level | χ2 | p | ||
|---|---|---|---|---|---|---|---|---|---|
| Low (n=38) | High(n=30) | Low (n=38) | High(n=30) | ||||||
| Age(years) | 1.36 | 0.243 | Clinical stage | 3.51 | 0.061 | ||||
| <58 | 18(47.4%) | 10(33.3%) | I | 20(52.6%) | 9(30.0%) | ||||
| ≥58 | 20(52.6%) | 20(66.7%) | II+III+IV | 18(47.4%) | 21(70.0%) | ||||
| Sex | 0.5 | 0.481 | PLT (×109/L) | 1.56 | 0.211 | ||||
| Male | 21(55.2%) | 14(46.6%) | <251 | 21(55.3%) | 12(40.0%) | ||||
| Female | 17(44.8%) | 16(53.4%) | ≥251 | 17(44.7%) | 18(60.0%) | ||||
| Tumor size(cm) | 0.68 | 0.411 | NE(×109/L) | 0.002 | 0.965 | ||||
| <2.79 | 19(50.0%) | 18(60.0%) | <5.34 | 23(60.5%) | 18(60.0%) | ||||
| ≥2.79 | 19(50.0%) | 12(40.0%) | ≥5.34 | 15(39.5%) | 12(40.0%) | ||||
| Pathologic type | 3.76 | 0.053 | NLR | 0.14 | 0.712 | ||||
| NSCLC | 37(97.4%) | 24(80.0%) | <4.01 | 25(65.8%) | 21(70.0%) | ||||
| SCLC | 1(2.6%) | 6(20.0%) | ≥4.01 | 13(34.2%) | 9(30.0%) | ||||
| Treatment | 5.46 | 0.019 | PLR | 1.09 | 0.297 | ||||
| Surgery | 13(34.2%) | 3(10.0%) | <183.1 | 25(65.8%) | 16(53.3%) | ||||
| Systemic therapy | 25(65.8%) | 27(90.0%) | ≥183.1 | 13(34.2%) | 14(46.7%) | ||||
| T classification | 7.84 | 0.005 | dNLR | 1.19 | 0.276 | ||||
| T1+T2 | 33(86.8%) | 17(56.7%) | <2.2 | 24(63.2%) | 15(50.0%) | ||||
| T3+T4 | 5(13.2%) | 13(43.3%) | ≥2.2 | 14(36.8%) | 15(50.0%) | ||||
| N classification | 1.73 | 0.189 | LC(×109/L) | 0.19 | 0.666 | ||||
| N0 | 25(65.8%) | 15(50.0%) | <1.5 | 17(44.7%) | 15(50.0%) | ||||
| N1+N2+N3 | 13(34.2%) | 15(50.0%) | ≥1.5 | 21(55.3%) | 15(50.0%) | ||||
| Metastasis tatus | 0.66 | 0.416 | |||||||
| Yes | 31(81.6%) | 22(73.3%) | |||||||
| No | 7(18.4%) | 8(26.7%) | |||||||
Values in bold mean p<0.05.